New approaches in pharmacology: Numerical modelling and simulation;Modélisation numérique et simulation: Nouvelles applications en pharmacologie

Therapie

Volumn 60, Issue 1, 2005, Pages 1-15

  Boissel, Jean Pierre ^a,c   Cucherat, Michel ^a,b   Nony, Patrice ^a   Dronne, Marie Aimée ^a   Kassaï, Behrouz ^a   Chabaud, Sylvie ^a,c  

^a LOUIS PRADEL HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Drug development; Drug innovation; Numerical modelling; Simulation; Therapeutic models

Indexed keywords

BIOLOGICAL MODEL; CEREBROVASCULAR ACCIDENT; CLINICAL PHARMACOLOGY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG TOLERANCE; FRANCE; JAPAN; NEW ZEALAND; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 16344363975     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2005001     Document Type: Article

References (33)

1. Reeves H. Oiseaux, merveilleux oiseaux, les dialogues du ciel et de la vie. Paris: Points-Sciences. Edition du Seuil, 1998
2. Complexité. In: Lecourt D, éditeur. Dictionnaire d'histoire et philosophie des sciences. Paris: Presse Universitaires de France (PUF), 1999
3. Wheng G, Bhalla US, Iyengar R. Complexity in biological signaling systems. Science 1999; 284: 92-6
4. Palsson B. The challenge of in silica biology. Nat Biotechnol 2000; 18: 1147-50
5. McCulloch AD, Huber G. Integrative biological modelling in silica. In: Bock G, Goode JA. editors. 'In silica' simulation of biological processes. Novartis Foundation Symposium 247. London: John Wiley & Sons. 2002: 4-19
6. Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-4
7. Entretien avec François Jacob, propos recueillis par M Alberganti, H Morin, JY Nau. Le Monde 2003 Avr 9; pp 25
8. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002; 296: 692-5
9. Noble D. Modeling the heart: from genes to cells to the whole organ. Science 2002; 295: 1678-82
10. Francheteau P, Steimer JL, Merdjan H, et al. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm 1993; 21: 489-514
11. Nony P, Cucherat M, Boissel JP. Revisiting the effect compartment through timing errors in drug administration. Trends Pharmacol Sci 1998; 19: 49-54
12. Chabaud S, Girard P, Nony P, et al. Clinical trial simulation using therapeutic effect modelling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29: 339-63
13. Nony P, Boissel JP. Use of sensitivity functions to characterise and compare the forgiveness of drugs. Clin Pharmacokinet 2002; 41: 371-80
14. Duval V, Chabaud S, Girard P, et al. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 8: 1010-8
15. Bock G, Goode JA. editors. 'In silica' simulation of biological processes. Novartis Foundation Symposium 247. Chichester: John Wiley & Sons, 2002
16. AfCS-Nature: the signaling gateway [online]. Available from URL: http://www.afcs.org [Accessed 2004 Nov 19]
17. Loew LM, Schaff JC. The virtual-cell: a software environment for computational cell biology. Trends Biotechnol 2001; 19: 401-6
18. Tomita M, Hashimoto K, Takahashi K, et al. E-cell: software environment for whole cell simulation. Bioinformatics 1999; 15: 72-84
19. Noble D, Levin J, Scott W. Biological simulations in drug discovery. Drug Discov Today 1999; 4: 10-6
20. Moolgavkar S. Multistage model for carcinogenesis. J Natl Cancer Inst 1980; 65: 215-6
21. Moolgavkar S, Krewski D, Schwarz M. Mechanisms of carcinogenesis and biologically based models for estimation and prediction of risk. IARC Sci Publ 1999; 131: 179-237
22. Portier CJ, Kopp-Schneider A, Sherman CD. Using cell replication data in mathematical modeling in carcinogenesis. Environ Health Perspect. 1993; 101 Suppl. 5: 79-86
23. Ribba B, Alarcon T, Marron K, et al. A mathematical model of doxorubicin treatment efficacy on non-Hodgkin's lymphoma: investigation of current protocol through theoretical modelling result. Bull Math Biol 2005; 67 (1): 79-99
24. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95
25. Service RF. Exploring the systems of life. Science 1999; 284: 80-3
26. Gueyffier F, Dib M, Boissel JP. Biomarqueurs biologiques: utilisation pour le développement et l'approbation des médicaments. Therapie 2001; 56: 355-61
27. Girard P, Cucherat M, Guez D. Simulation des essais cliniques dans le développement des médicaments. Therapie 2004; 59: 287-95
28. Duffull SB, Chabaud S, Nony P, et al. A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sc 2000; 10: 285-94
29. Gueyffier F, Cornu C, Bossard N, et al. Intérêt pronostique de la mesure ambulatoire de pression artérielle en France. Arch Mal Coeur Vaiss 1999; 92: 1151-5
30. Dronne MA, Boissel JP, Grenier E, et al. Mathematical modelling of ischémic stroke: an integrative approach. Acta Biotheoretica 2004; 52: 255-72
31. Gueyffier F, Boutitie F, Boissel JP, et al. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997; 126: 761-7
32. Kassai B, Gueyffier F, Boissel JP, et al. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003; 56: 977-82
33. Boissel JP. Note sur l'épistémiologie de la pharmacologie clinique: confrontation à l'approche de Karl Popper. Therapie 1999; 54: 67-73